Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMCR
#1803
Immunocore Holdings plc American Depositary Shares
32.300
0
+2.28%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
+2.28%
Monthly Change
-8.00%
6 month change
-3.52%
Cambio anual
-3.52%
Cierres anteriores
31.580
0
Open
32.300
0
Bid
Ask
Low
32.300
0
High
32.300
0
Volumen
17
Markets
Acciones
Atención Sanitaria
IMCR
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Total assets
1.08 B
1.01 B
1.03 B
1.08 B
1.1 B
1.07 B
Total liabilities
706.81 M
648.79 M
649.53 M
693.91 M
705.94 M
686.24 M
Total equity
377.83 M
360.72 M
378.48 M
388.48 M
396.56 M
381.03 M
Total liabilities & shareholders' equities
1.08 B
1.01 B
1.03 B
1.08 B
1.1 B
1.07 B
Total debt
—
—
—
—
—
—
Net debt
—
—
—
—
—
—
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
Noticias
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Immunocore earnings ahead as melanoma pipeline advances
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why
SNY Stock Falls After Board Suddenly Makes Leadership Change
GSK Gets EU Approval for Expanded Use of Nucala in COPD